Cargando…
The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
SIMPLE SUMMARY: More than a third of all colorectal cancers have a KRAS mutation. The complex biology of these cancers has challenged the development of direct targeting inhibitors. Substantial leaps have been made in recent years, with a wave of new generation inhibitors able to specifically target...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136970/ https://www.ncbi.nlm.nih.gov/pubmed/37190303 http://dx.doi.org/10.3390/cancers15082375 |